Chemotherapy News and Research

Latest Chemotherapy News and Research

Researchers demonstrate that MSNs can effectively suppress tumors in mice

The application of nanotechnology in the field of drug delivery has attracted much attention in recent years. In cancer research, nanotechnology holds great promise for the development of targeted, localized delivery of anticancer drugs, in which only cancer cells are affected.

12 Jul 2010

Survival rates for people diagnosed with once-deadly cancer increase: Cancer Research UK

People diagnosed with breast, bowel and ovarian cancers and non-Hodgkin's lymphoma are today twice as likely to survive for at least 10 years as those diagnosed in the early 1970s according to new figures1 released by Cancer Research UK.

12 Jul 2010

Semuloparin reduces incidence of VTE in orthopedic surgery patients, study finds

An ultra-low-molecular-weight heparin called semuloparin has been found to reduce the incidence of venous thromboembolism in orthopedic surgery patients in a large clinical program being lead by a steering committee chaired by McMaster University professor Dr. Alexander Turpie.

9 Jul 2010

Promising study may lead to potential new therapeutics for women facing triple-negative breast cancer

Using a small molecule decoy, investigators funded by the Samuel Waxman Cancer Research Foundation have managed to block protein interactions and induce epigenetic reprogramming in human and mouse breast cancer cells, essentially changing the gene expression of breast cancer cells to behave in a more normal manner.

9 Jul 2010

Musashi 2 protein predicts progression of AML and CML, identify researchers

Researchers at Whitehead Institute and Children's Hospital Boston have identified a protein, called Musashi 2, that is predictive of prognosis in acute myeloid leukemia and chronic myeloid leukemia patients.

9 Jul 2010

Study suggests Perfusion CT as noninvasive tool in diagnosis of hepatic toxicity

Liver damage is common in patients with tumor following chemotherapy. Although early liver damage causes no symptoms and is reversible in most patients, it occasionally progresses to more severe liver impairment, which may be irreversible, it is thus necessary to demonstrate the presence and severity of drug-related parenchymal changes.

9 Jul 2010

Study finds EUS associated with improved outcomes in patients with localized pancreatic cancer

A new study has found that endoscopic ultrasound (EUS) is associated with improved outcomes in patients with localized pancreatic cancer, possibly due to the detection of earlier cancers and improved stage-appropriate management, including more selective performance of curative intent surgery. This is the first study to analyze a large population-based cancer registry and demonstrate that EUS evaluation is associated with improved pancreatic cancer survival.

9 Jul 2010

IRIC scientists identify vitamin B3 as potential antifungal treatment

A team of scientists from the Institute for Research in Immunology and Cancer (IRIC) of the University of Montreal have identified vitamin B3 as a potential antifungal treatment. Led by IRIC Principal Investigators Martine Raymond, Alain Verreault and Pierre Thibault, in collaboration with Alaka Mullick, from the Biotechnology Research Institute of the National Research Council Canada, the study is the subject of a recent article in Nature Medicine.

9 Jul 2010

Idera announces issuance of patents for synthetic immune modulatory oligonucleotides targeted to TLRs

Idera Pharmaceuticals, Inc. today announced the issuance of patents covering compositions and methods of using its synthetic immune modulatory oligonucleotides targeted to Toll-like receptors (TLRs). The Company's intellectual property portfolio currently contains over 500 patents and patent applications worldwide and includes claims for TLR-targeted compounds, second-generation antisense chemistry, and oral delivery of certain oligonucleotides.

8 Jul 2010

ESMO releases revised set of clinical guidelines for cancer patient care

The European Society for Medical Oncology just released an enhanced and revised set of clinical recommendations designed to help oncologists deliver the best quality care to their patients.

8 Jul 2010

Scientists shrink distant sarcomas with genetically reprogrammed herpes virus and anti-vascular drug

Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice – still an elusive goal when treating humans with cancer, according to a study in the July 8 Gene Therapy.

8 Jul 2010

Scientists use genetically reprogrammed herpes virus to shrink distant sarcomas

Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice - still an elusive goal when treating humans with cancer, according to a study in the July 8 Gene Therapy.

8 Jul 2010

Report investigates clear cell ICC

Intrahepatic cholangiocarcinoma is a cancer of the bile duct in the liver. The clear cell subtype of ICC is a rare cancer; until now, only 8 cases have been reported. The number of reports is so small that a detail description of clear cell ICC is valuable.

8 Jul 2010

Olaparib shows promising results against inherited forms of breast and ovarian cancer

Olaparib, a new type of experimental drug called a PARP inhibitor, has shown promising results against inherited forms of breast and ovarian cancer in two small clinical trials led by scientists at the Breakthrough Breast Cancer Research Unit at King's College London.

8 Jul 2010

MonoSol partner Strativa receives FDA approval for Zuplenz OSF

MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in film pharmaceutical products, in collaboration with APR Applied Pharma Research s.a. of Switzerland and Labtec GmbH of Germany, today announced that its partner, Strativa Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for Zuplenz® oral soluble film for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.

8 Jul 2010

Epeius Biotechnologies receives notice of allowance from USPTO for gene delivery platform

Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances covering tumor-targeted gene delivery and precision-targeted cancer immunotherapy, respectively.

7 Jul 2010

Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients

The combination of Biothera's experimental drug Imprime PGG® and Erbitux® (cetuximab) doubled the historical overall response rate and the time to progression of second- and third-line metastatic colorectal cancer patients treated with Erbitux monotherapy. The data was released last weekend at the 13th World Congress on Gastrointestinal Cancer at the European Society for Medical Oncology (ESMO).

7 Jul 2010

New Center for Image-Guided Intervention opened at MSKCC

Image-guided interventions are revolutionizing cancer diagnosis and treatment. MSKCC's new Center for Image-Guided Intervention (CIGI), which opened in June, offers cancer patients the most advanced, minimally invasive diagnostic and treatment options in a unique multidisciplinary setting designed to foster rapid innovations in cancer care.

7 Jul 2010

Multicolor quantum dots can distinguish Reed-Sternberg cells, article shows

The tunable fluorescent nanoparticles known as quantum dots make ideal tools for distinguishing and identifying rare cancer cells in tissue biopsies, Emory and Georgia Tech scientists have demonstrated.

7 Jul 2010

Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer

Genentech, a member of the Roche Group, today announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies.

7 Jul 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Researchers demonstrate that MSNs can effectively suppress tumors in mice

Survival rates for people diagnosed with once-deadly cancer increase: Cancer Research UK

Semuloparin reduces incidence of VTE in orthopedic surgery patients, study finds

Promising study may lead to potential new therapeutics for women facing triple-negative breast cancer

Musashi 2 protein predicts progression of AML and CML, identify researchers

Study suggests Perfusion CT as noninvasive tool in diagnosis of hepatic toxicity

Study finds EUS associated with improved outcomes in patients with localized pancreatic cancer

IRIC scientists identify vitamin B3 as potential antifungal treatment

Idera announces issuance of patents for synthetic immune modulatory oligonucleotides targeted to TLRs

ESMO releases revised set of clinical guidelines for cancer patient care

Scientists shrink distant sarcomas with genetically reprogrammed herpes virus and anti-vascular drug

Scientists use genetically reprogrammed herpes virus to shrink distant sarcomas

Report investigates clear cell ICC

Olaparib shows promising results against inherited forms of breast and ovarian cancer

MonoSol partner Strativa receives FDA approval for Zuplenz OSF

Epeius Biotechnologies receives notice of allowance from USPTO for gene delivery platform

Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients

New Center for Image-Guided Intervention opened at MSKCC

Multicolor quantum dots can distinguish Reed-Sternberg cells, article shows

Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer

Cancer Research - Second Edition eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in